Skip to main content

Table 2 Plasma Aβ40 levels following transient GSI treatment in Tg2576 mice

From: Transient pharmacologic lowering of Aβ production prior to deposition results in sustained reduction of amyloid plaque pathology

Treatment Time

Treatment Groups

Plasma Aβ40 (pM)

4-7 Month

Ly-411,575

341.3 ± 20.1 (81%)

Control

1742.6 ± 103.5

7-10 Month

Ly-411,575

327.5 ± 18.5 (79%)

Control

1520.7 ± 100.8

12-15 Month

Ly-411,575

427.3 ± 31.4 (70%)

Control

1388.4 ± 223.2

  1. Tg2576 mice were transiently dosed with GSI LY-411,575(2.5 mg/kg/day) at indicated time points. After GSI treatment was discontinued (on last day of treatment), plasma from groups of mice (n =3/group) was collected and plasma Aβ40 levels were measured by ELISA.
  2. -Numbers in parenthesis represent percent reduction in Aβ levels.
Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326